首页> 美国卫生研究院文献>Cancer Management and Research >Using LC–MS/MS-based targeted proteomics to monitor the pattern of ABC transporters expression in the development of drug resistance
【2h】

Using LC–MS/MS-based targeted proteomics to monitor the pattern of ABC transporters expression in the development of drug resistance

机译:使用基于LC-MS / MS的靶向蛋白质组学来监测耐药性发展过程中ABC转运蛋白表达的模式

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

PurposeThe overexpression of ATP-binding cassette transporters (ABC transporters), mainly including permeability glycoproteins (P-gp), multidrug resistance (MDR)-related protein 1 (MRP1), and breast cancer resistance proteins (BCRP), is one of the main reasons for the development of MDR which directly leads to chemotherapy failure. However, most of the currently used detection methods in MDR-related studies are qualitative or semiquantitative, but not quantitative. As a result, the measurement criteria of different experiments are not unified. Moreover, there are many contradictory results of the studies of the induction effect of drugs on ABC transporters. So, it is necessary to establish a quantitative assay for the quantification of P-gp, MRP1, and BCRP to study the mechanism of drug resistance.
机译:目的ATP结合盒转运蛋白(ABC转运蛋白)的过表达主要是通透性糖蛋白(P-gp),多药耐药性(MDR)相关蛋白1(MRP1)和乳腺癌耐药蛋白(BCRP)的主要表达之一导致直接化疗失败的MDR的原因。但是,与MDR相关的研究中,当前大多数使用的检测方法是定性或半定量的,但不是定量的。结果,不同实验的测量标准不统一。而且,关于药物对ABC转运蛋白的诱导作用的研究有许多矛盾的结果。因此,有必要建立一种定量检测P-gp,MRP1和BCRP的定量方法,以研究耐药性的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号